| Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial JY Blay, C Serrano, MC Heinrich, J Zalcberg, S Bauer, H Gelderblom, ... The Lancet Oncology 21 (7), 923-934, 2020 | 359 | 2020 |
| Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas SP Chawla, AP Staddon, LH Baker, SM Schuetze, AW Tolcher, ... Journal of Clinical Oncology 30 (1), 78-84, 2012 | 294 | 2012 |
| Update on the biology and therapy of gastrointestinal stromal tumors G D'amato, DM Steinert, JC McAuliffe, JC Trent Cancer control 12 (1), 44-56, 2005 | 291 | 2005 |
| Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib KA Janeway, KH Albritton, AD Van Den Abbeele, GZ D'Amato, ... Pediatric blood & cancer 52 (7), 767-771, 2009 | 182 | 2009 |
| Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies … ST Mahmood, S Agresta, CE Vigil, X Zhao, G Han, G D'Amato, CE Calitri, ... International journal of cancer 129 (8), 1963-1969, 2011 | 140 | 2011 |
| Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor SM Schuetze, V Bolejack, E Choy, KN Ganjoo, AP Staddon, WA Chow, ... Cancer 123 (1), 90-97, 2017 | 123 | 2017 |
| Nirogacestat, a γ-secretase inhibitor for desmoid tumors M Gounder, R Ratan, T Alcindor, P Schöffski, WT Van Der Graaf, BA Wilky, ... New England Journal of Medicine 388 (10), 898-912, 2023 | 122 | 2023 |
| Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas SP Chawla, AW Tolcher, AP Staddon, SM Schuetze, GZ D’Amato, JY Blay, ... Journal of Clinical Oncology 24 (18_suppl), 9505-9505, 2006 | 78 | 2006 |
| Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial SP Chawla, AW Tolcher, AP Staddon, S Schuetze, GZ D'Amato, JY Blay, ... Journal of Clinical Oncology 25 (18_suppl), 10076-10076, 2007 | 77 | 2007 |
| Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or … S Patel, M von Mehren, DR Reed, P Kaiser, J Charlson, CW Ryan, ... Cancer 125 (15), 2610-2620, 2019 | 67 | 2019 |
| Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS … S Bauer, MC Heinrich, S George, JR Zalcberg, C Serrano, H Gelderblom, ... Clinical cancer research 27 (23), 6333-6342, 2021 | 43 | 2021 |
| Soft tissue sarcoma GD Demetri, LH Baker, RS Benjamin, ES Casper, EU Conrad 3rd, ... Journal of the National Comprehensive Cancer Network: JNCCN 5 (4), 364-399, 2007 | 43 | 2007 |
| Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis AP Espejo-Freire, A Elliott, A Rosenberg, PA Costa, P Barreto-Coelho, ... Cancers 13 (19), 4816, 2021 | 41 | 2021 |
| Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature G D’Amato, CR Lima, JJ Mahany, C Muro-Cacho, EB Haura Lung Cancer 44 (3), 381-390, 2004 | 40 | 2004 |
| Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas AC Shor, SV Agresta, GZ D'amato, VK Sondak Cancer Control 15 (1), 47-54, 2008 | 33 | 2008 |
| Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib SM Schuetze, V Bolejack, DG Thomas, M Von Mehren, S Patel, ... JAMA oncology 4 (6), 814-820, 2018 | 32 | 2018 |
| Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study JR Zalcberg, MC Heinrich, S George, S Bauer, P Schöffski, C Serrano, ... The Oncologist 26 (11), e2053-e2060, 2021 | 31 | 2021 |
| Sunitinib treatment of pediatric metastatic GIST after failure of imatinib KA Janeway, DC Matthews, JE Butrynski, GZ D’Amato, S Agresta, ... Journal of Clinical Oncology 24 (18_suppl), 9519-9519, 2006 | 27 | 2006 |
| INVICTUS: a Phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as≥ 4th-line therapy in patients with advanced … M Von Mehren, C Serrano, S Bauer, H Gelderblom, S George, M Heinrich, ... Annals of Oncology 30, v925-v926, 2019 | 25 | 2019 |
| Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas CE Vigil, AA Chiappori, CA Williams, HH Shrager, BL Murray, DG Letson, ... Journal of Clinical Oncology 26 (15_suppl), 10535-10535, 2008 | 25 | 2008 |
